Ulrich Rumenapp

As pharmaceutical companies increasingly rely on CDMOs to deliver complex therapies and expand manufacturing capacity, strong partnerships have never been more critical. These relationships play a vital role in ensuring life-saving medicines reach patients safely and on time. 

• In your opinion, what are the three most important qualities of a successful pharma–CDMO partnership?
• How can both parties navigate challenges around cost, quality, risk, and ownership while maintaining trust?
• To share lessons learned from partnerships that succeeded (or failed) and how have those experiences shaped future collaborations? 

Ahead of the conference, we launched a delegate survey to gather insights on what participants hoped to gain from the three-day event, as well as the key challenges currently facing pharma contract manufacturing. The survey explored critical topics such as supply chain disruptions, the impact of geopolitical tensions, and the ongoing debate between localisation and centralisation.